Form 4: Daxor Corp Director Caleb DesRosiers Reports Stock Option Grant

Director Caleb DesRosiers reports acquisition of stock options in Daxor Corp.

Summary

• Caleb DesRosiers, a director of Daxor Corp, filed a Form 4 on July 17, 2024, reporting a transaction.
• The transaction involved the acquisition of stock options to purchase 2,500 shares of Daxor Corp common stock.
• These options were granted on July 11, 2022, but are contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan.
• The options have an exercise price of $9.20 and expire on July 15, 2029.
• The options vest in three installments: 833 on July 15, 2024; 833 on July 15, 2025; and 834 on July 15, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants, a common practice in corporate governance.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company over the next three years.

Risks

• The stock option grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan; failure to obtain this approval would nullify the grant.

Industry Context

Stock option grants are a common form of executive compensation in the healthcare industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, particularly in growth-oriented sectors like healthcare.
• The size of the grant (2,500 shares) should be evaluated in the context of Daxor's overall share count and the director's existing equity holdings to determine its significance.
• Vesting schedules are generally structured to incentivize long-term performance, with three-year vesting being a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see the grant as a positive sign of the company's commitment to incentivizing its leadership.

Next Steps

• SEC approval of the amendment to the Daxor Corporation 2020 Incentive Compensation Plan is required for the stock options to be fully granted.

Key Dates